Geneva, Switzerland & Barcelona, Spain – [March 30, 2026] – ABCDx, a leader in blood-based brain diagnostics and AI-enabled neurovascular decision support, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent covering a method for selecting stroke patients for reperfusion therapy.
The patent, originating from Fundació Hospital Universitari Vall d’Hebron – Institut de Recerca (VHIR) and exclusively licensed to ABCDx, reinforces the company’s leadership in large vessel occlusion (LVO) triage and thrombectomy pathway optimization, one of the highest-value unmet needs in acute stroke care.
This newly allowed U.S. patent further strengthens ABCDx’s already substantial international intellectual property portfolio spanning stroke, traumatic brain injury (TBI), transient ischemic attack (TIA), and AI-powered biomarker algorithms, across the United States, China, Europe, and other key jurisdictions.
A uniquely deep neurodiagnostic asset base
Beyond patents alone, ABCDx has built over more than a decade one of the most comprehensive asset platforms in emergency brain diagnostics, including:
-Multiple granted and allowed patent families in stroke, TBI, pediatric TBI, TIA, and prognosis
-Exclusive lifetime licenses and co-ownership agreements with leading institutions including VHIR and the University of Geneva
-Clinical data sets exceeding thousands of patients
-Prospective ambulance and hospital validation studies
-AI-driven biomarker panel algorithms and smartphone-based decision support
-Regulatory ground work across Europe and the U.S.
-Point-of-care platform know-how spanning assay, software, and clinical workflow integration
Together, these assets position ABCDx not only as a diagnostics innovator, but as a strategic acquisition and partnering platform in acute neurovascular care.
Strategic significance
The newly allowed claims protect clinically actionable methods to identify patients most likely to benefit from reperfusion therapies such as thrombectomy, directly supporting faster routing to comprehensive stroke centers and improved patient outcomes.
“This newly allowed U.S.patent is highly strategic because it strengthens protection around one of the most critical clinical decisions in stroke, selecting the right patient for rapid reperfusion therapy,” said Jean-Charles Sanchez, CEO and Co-founder of ABCDx. “More importantly, it highlights the depth of the broader ABCDx asset platform we have assembled across stroke, TBI, AI, and point-of-care diagnostics, creating significant optionality for strategic partnerships, licensing, and broader corporate transactions.”
Positioned for strategic value realization
This milestone comes as ABCDx advances discussions around strategic partnerships and value realization initiatives across its stroke, TBI, and digital platform assets.
The company believes the combination of strong U.S. IP protection, large clinical datasets, exclusive institutional rights, and real-world implementation know-how creates a differentiated position in the global neurodiagnostic market.
About ABCDx
ABCDx is a Swiss-Spanish diagnostics company developing blood-based tests for brain injury and acute neurological conditions. Its portfolio spans stroke, traumatic brain injury, and related indications, with a focus on rapid, objective, and clinically actionable biomarkers.
Media Contact
Tamara Sefcovicova
PR, Marketing and Office OperationsSpecialist
